The safety of fondaparinux for the prevention and treatment of venous thromboembolism

Expert Opinion on Drug Safety

Volumn 4, Issue 4, 2005, Pages 707-721

  Turpie, Alexander G G ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Antithrombotic; Bleeding; Fondaparinux; Low molecular weight herapin; Pentasaccharide; Thromboprophylaxis; Treatment; Unfractionated herapin; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANTIVITAMIN K; ASPARTATE AMINOTRANSFERASE; DALTEPARIN; DIGOXIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO;

ABDOMINAL SURGERY; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG OVERDOSE; DRUG PROTEIN BINDING; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; KIDNEY DISEASE; LUNG EMBOLISM; META ANALYSIS; MOBILIZATION; NONHUMAN; ORTHOPEDIC SURGERY; POSTOPERATIVE CARE; REGIONAL ANESTHESIA; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CLINICAL TRIALS; HEMORRHAGE; HUMANS; POLYSACCHARIDES; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 21944443716     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.4.707     Document Type: Review

References (54)

1. WEITZ JI, HIRSH J, SAMAMA MM: New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126(3 Suppl.):S265-S286.
2. YIN ET, WESSLER S, STOLL PJ: Biological properties of the naturally occurring plasma inhibitor to activated Factor X. J. Biol. Chem. (1971) 246(11):3703-3711.
3. WALENGA JM, JESKE WP, BARA L, SAMAMA MM, FAREED J: Biochemical and pharmacologic rationale for the development of a synthetic pentasaccharide. Thromb. Res. (1997) 86(1):1-36.
4. HERBERT JM, PETITOU M, LORMEAU JC et al.: SR 90107/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc. Drug Rev. (1997) 15(1):1-26.
5. PETITOU M, DUCHAUSSOY P, LEDERMAN I et al.: Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide O-(2-deoxy-2-sulfamido-6-O-sulfo-alpha-D-glucopyranosyl)-(1-4)-O- (beta-D-glucopyranosyluronic acid)-(1-4)-O-(2-deoxy-2-sulfamido-3,6- di-O-sulfo-alpha-D-glucopyranosyl)-(1-4)-O-(2-O-sulfo-alpha-L- idopyranosyluronic acid)-(1-4)-2-deoxy-2-sulfamido-6-O-sulfo-D-glucopyranose decasodium salt, a heparin fragment having high affinity for antitrombin III. Carbohydr. Res. (1986) 147(2):221-236.
6. TURPIE AGG, GALLUS AS, HOEK JA: A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N. Engl. J. Med. (2001) 344(9):619-625.
7. LASSEN MR, BAUER KA, ERIKSSON BI, TURPIE AGG for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee: Postoperative fondaparinux versus preoperarive enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet (2002) 359(9319):1715-1720.
8. TURPIE AGG, BAUER KA, ERIKSSON BI, LASSEN MR for the PENTATHLON 2000 Study Steering Committee: Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet (2002) 359(9319):1721-1726.
9. BAUER KA, ERIKSSON BI, LASSEN MR, TURPIE AGG for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N. Engl. J. Med. (2001) 345(18):1305-1310.
10. ERIKSSON BI, BAUER KA, LASSEN MR, TURPIE AGG for the Steering Committee of the Pentasaccharide in Hip Fracture Surgery Study: Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N. Engl. J. Med. (2001) 345(18):1298-1304.
11. ERIKSSON BI, LASSEN MR, on behalf of the PENTHIFRA-PLUS investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery. A multicenter, randomized, placebo-controlled, double-blind study. Arch. Intern. Med. (2003) 163(11):1337-1342.
12. TURPIE AGG, BAUER KA, ERIKSSON BI, LASSEN MR for the Steering Committees of the Pentasaccharide Orthopedic Prophylactic Studies: Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized studies. Arch. Intern. Med. (2002) 162(16):1833-1840.
13. AGNELLI G, BERGQVIST D, COHEN A, GALLUS AS, GENT M: A randomized double-blind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra) and preoperative dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: The PEGASUS Study. Blood (2003) 102(11):Abstract 40.
14. COHEN AT, DAVIDSON BL, GALLUS AS et al.: Fondaparinux for the prevention of venous thromboembolism in acutely ill medical patients. Blood (2003) 102(11):Abstract 42.
15. THE REMBRANDT INVESTIGATORS: Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity. A Phase II evaluation. Circulation (2000) 102(22):2726-2731.
16. BULLER HR, DAVIDSON BL, DECOUSUS H et al.: Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann. Intern. Med. (2004) 140(11):867-873.
17. BULLER HR, DAVIDSON BL, DECOUSUS H et al.: Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med. (2003) 349(18):1695-1702.
18. COUSSEMENT PK, BASSAND JP, CONVENS C et al.: A synthetic Factor Xa-inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. Eur. Heart. J. (2001) 22(18):1716-1724.
19. SIMMOONS M, BOBBINK IW, BOLAND J et al.: A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes; The Pentasaccharide in Unstable Angina (PENTUA) study. J. Am. Coll. Cardiol. (2004) 43(12):2183-2190.
20. VUILLEMENOT A, SCHIELE F, MENEVEAU N et al.: Efficacy of a synthetic pentasaccharide, a pure Factor Xa inhibitor, as an antithrombotic agent. A pilot study in the setting of coronary angioplasty. Thromb. Haemost. (1999) 81(2):214-220.
21. GEERTS WH, PINEO GF, HEIT JA et al.: Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126(3 Suppl.):S338-S400.
22. BONEU B, NECCIARI J, CARIOU R et al.: Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb. Haemost. (1995) 74(6):1468-1473.
23. LIEU C, SHI J, DONAT F et al.: Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs. Clin. Pharmacokinet. (2002) 41(Suppl.):19-26.
24. PAOLUCCI F, CLAVIES MC, DONAT F, NECCIARI J: Fondaparinux sodium mechanism of action: identificacion of specific binding to purified and human plasma-derived proteins. Clin. Pharmacokinet. (2002) 41(Suppl.):11-18.
25. FAAIJ RA, BURGGRAAF J, SCHOEMAKER RC, DE GREEF R, COHEN AF: Absence of interaction between the synthetic pentasaccharide fondaparinux sodium and oral warfarin. Clin. Pharmacokinet. (2002) 41(Suppl.):27-29.
26. OLLIER C, SANTONI A, FAAIJ RA et al.: Interaction of Fondaparinux sodium with acetylsalicylic acid and piroxicam in healthy male volunteers. Clin. Pharmacokinet. (2002) 41(Suppl.):31-37.
27. MANT T, FOURNIÉ P, OLLIER C, DONAT F, NECCIARI J: Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers. Clin. Pharmacokinet. (2002) 41(Suppl.):39-45.
28. ELALAMY I, LECRUBIER C, POTEVIN F et al.: Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin dependent factor of twenty-five patients with heparin associated thrombocytopenia. Thromb. Haemost. (1995) 74(5):1384-1385.
29. AHMAD S, JESKE WP, WALENGA JM et al.: Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin. Appl. Thromb. Hemost. (1999) 5(4):259-266.
30. SAVI P, CHONG BH, GREINACHER A et al.: Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies. A blinded comparative multicenter study with unfractionated heparin. Blood (2004) 105(1):139-144.
31. AMIRAL J, LORMEAU JC, MARFAING-KOKA A et al.: Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coag. Fibrinolysis (1997) 8(2):114-117.
32. MATZIOLIS G, PERKA C, DISCH A, ZIPPEL H: Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int. (2003) 73(4):370-379.
33. LAGRANGE F, VERGNES C, BRUN JL et al.: Absence of placental transfer of pentasaccharide (fondaparinux, Arixtra®) in the dually perfused cotyledon in vitro. Thromb. Haemost. (2002) 87(5):831-835.
34. ALBAN S: The 'precautionary principle' as a guide for future drug development. Eur. J. Clin. Invest. (2005) 35(Suppl. 1):33-44.
35. TURPIE AGG, BAUER KA, ERIKSSON BI, LASSEN MR: Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb. Haemost. (2003) 90(2):364-366.
36. DAVIDSON B, TURPIE AGG, COLWELL C, KWONG LM: Early versus delayed initiation of fondaparinux prophylaxis to prevent postoperative pulmonary embolism: a clinical endpoint study. Chest (2004) 126(4):S783.
37. WALENGA JM, HOPPENSTEADT D, MAYUGA M, SAMAMA MM, FAREED J: Functionality of pentasaccharide depends on endogenous antithrombin levels. Blood (2000) 96(11):817a.
38. BIJSTERVELD NR, MOONS AH, BOEKHOLDT M et al.: Ability of recombinant activated Factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation (2002) 106(20):2550-2554.
39. BAUER KA, ERIKSSON BI, LASSEN MR, TURPIE AGG: No episode of thrombocytopenia after four-week administration of fondaparinux, a new synthetic and selective inhibitor of Factor Xa, in the PENTHIFRA-PLUS study. J. Thromb. Haemost. (2003) 1(Suppl. 1):P2050.
40. WARKENTIN TE, COOK RJ, MARDER VJ, KELTON JG: Comparison of heparin-induced thrombocytopenia antibody generation and in vitro cross-reactivity after elective hip or knee replacement surgery in patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood (2003) 102(11):Abstract 569.
41. PARODY R, OLIVER A, SOUTO JC, FONTCUBERTA J: Fondaparinux (Arixtra) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica (2003) 88(11):ECR32.
42. D'AMICO EA, VILLACA PR, GUALANDRO SF, BASSITT RP, CHAMONE DA: Successful use of Arixtra in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia. J. Thromb. Haemost. (2003) 1(11):2452-2453.
43. LIAN EC, CHUA L, OBERSTEIN E: Long-term use of fondaparinux in a patient with antiphospholipid syndrome, heparin-induced thrombocytopenia and refractoriness to coumarin. Blood (2003) 102(11):Abstract 4206.
44. RUBIN N, RUBIN J: Treatment of heparin induced thrombocytopenia with thrombosis (HITT) in pregnancy with fondaparinux. Blood (2003) 102(11):Abscract 4190.
45. KUO KHM, KOVACS MJ: Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Blood (2003) 102(11):Abstract 1147.
46. HARENBERG J, JORG I, FENYVESI T: Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica (2004) 89(8):1017-1018.
47. LASSEN MR, ERIKSSON BI: Absence of transaminase increase after four-week administration of fondaparinux (Arixtra®), a new synthetic and selective inhibitor of Factor Xa, in the PENTHIFRA-PLUS study. J. Thromb. Haemost. (2003) 1(Suppl. 1):P2052.
48. FRANCIS CW: Ximelagatran: a new oral anticoagulant. Best Pract. Res. Clin. Haematol. (2004) 17(1):139-152.
49. COHEN AT, DAVIDSON BL, GALLUS AS et al.: Thromboprophylaxis with fondaparinux in acutely ill medical patients aged 75 years or more. Int. Angiol. (2004) 23(Suppl. 1):213.
50. COHEN AT, DAVIDSON BL, GALLUS AS et al.: Thromboprophylaxis with fondaparinux in acutely ill medical patients with moderate renal impairment. Int. Angiol. (2004) 23(Suppl. 1):213.
51. DEMPLE CE: Minor transplacental passage of fondaparinux in vivo. N. Engl. J. Med. (2004) 350(18):1914-1915.
52. LASSEN MR: The use of regional anesthesia in orthopedic surgery. Lessons from the fondaparinux database. In: EuroSurgery 2002. Monduzzi (Ed.) Bologna (2002) 39-42.
53. BOUVET E: A newly-designed syringe for safer and more convenient administration of fondaparinux. Int. Angiol. (2004) 23(Suppl. 1):125.
54. PAOLUCCI F, FRASA H, VAN AARLE F et al.: Two sensitive and rapid chromogenic assays of fondaparinux sodium (Arixtra®) in human plasma and other biological matrices. Clin. Lab. (2003) 49(9-10):451-460.